Quick answer: what is Petrelintide?
Petrelintide is a long-acting amylin analog in development for weight loss, part of the amylin class widely seen as the next major wave after GLP-1 drugs.
New to peptides? Start with what are peptides? and how do peptides work?
Quick facts
- Class
- Long-acting amylin analog
- Developers
- Zealand Pharma / Roche
- Studied for
- Chronic weight management
- Dosing
- Once weekly (investigational)
- Status
- Advancing to Phase 3 (2026); not approved
- Developers
- Zealand Pharma / Roche
- Mechanism
- Amylin receptor agonist (distinct from GLP-1)
- Status
- Advancing to Phase 3 (H2 2026)
Key takeaways
- It is engineered to resist clumping, giving it a once-weekly profile and the potential to be combined with other drugs.
- In Phase 2 it produced double-digit weight loss with tolerability reported close to placebo.
- Developed by Zealand Pharma and Roche, it is advancing to Phase 3 in 2026 and is not approved.
Overview
Petrelintide is a synthetic, long-acting analog of amylin — a hormone released alongside insulin that signals fullness. It is engineered to resist the clumping (fibrillation) that makes natural amylin hard to formulate, giving it a once-weekly profile and the potential to be combined with other agents.[1]
It sits at the front of what many in obesity medicine call the "next wave" after GLP-1 drugs. Developed by Zealand Pharma with Roche, it is advancing to Phase 3 trials, with initiation planned for the second half of 2026. It is not approved.
How it works
Amylin analogs act on amylin and calcitonin receptors in the brainstem and hypothalamus to promote satiety, slow stomach emptying, and reduce food intake — a mechanism distinct from the GLP-1 pathway.[2] That independence is the appeal: an amylin analog can be used on its own or paired with a GLP-1 or GIP drug to engage more than one appetite system at once.
Because it is designed to stay stable in solution, petrelintide is also being explored as a co-formulation partner, not just a standalone therapy.[1]
Clinical evidence
In Phase 2 (the ZUPREME program), petrelintide produced double-digit weight loss with tolerability reported as close to placebo — a profile that drew major industry attention to amylin monotherapy.[2][3] On the strength of those data, the developers announced in April 2026 that the compound would move into Phase 3.
As an investigational drug, its long-term efficacy and safety in large trials are not yet established, and it has not been reviewed by any regulator.
Safety & status
Reported side effects to date are mainly gastrointestinal (nausea), consistent with the drug class, and early tolerability has been a selling point relative to some GLP-1 agents. However, comprehensive human safety data await the Phase 3 program. Petrelintide is not FDA-approved and is not commercially available; anything sold under its name is unregulated. See our overview of weight-loss peptides.
Frequently asked questions
What is petrelintide?
Petrelintide (ZP8396) is a long-acting amylin analog being developed by Zealand Pharma and Roche as a once-weekly weight-loss treatment. Amylin analogs promote fullness through a pathway separate from GLP-1.
Is petrelintide approved?
No. Petrelintide is investigational. On the strength of Phase 2 data, its developers announced in 2026 that it would advance to Phase 3 trials, with initiation planned for the second half of 2026.
How does petrelintide compare to GLP-1 drugs?
Petrelintide works through the amylin pathway rather than the GLP-1 pathway, so it can be used on its own or combined with a GLP-1 or GIP drug. Early data suggested strong weight loss with tolerability close to placebo, but Phase 3 results are not yet available.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Fischer Munch H, Just R, Mosolff Mathiesen J, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. Peer-reviewed study
- Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. Peer-reviewed study
- Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026. Peer-reviewed study